Physicians' Academy for Cardiovascular Education

ESC Heart Failure 2019

PACE-CME.org was present at the ESC Heart Failure congress in Athens, Greece (May 25-28). Find reporting material of presented trending heart failure news here.

Incident hyperkalemia, RAASi use and outcomes in acute hospitalized HF patients

5' education - Aug. 26, 2019 - Joost Beusekamp
Joost Beusekamp shares results of his study on the association between potassium levels measured daily during hospitalization, treatment with RAASi and outcomes in acute HF patients.

ESC HF 2019 Joost Beusekamp shares results of his study on the association between potassium levels measured daily during hospitalization, treatment with RAASi and outcomes in acute HF patients.

A novel parameter for proximal tubular function in HF

5' education - Aug. 21, 2019 - Lisa Emmens
TmP/GFR is a novel parameter for tubular function. Lisa Emmens presents findings of her study on determinants of this parameter and its association with outcomes in HF patients.

ESC HF 2019 TmP/GFR is a novel parameter for tubular function. Lisa Emmens presents findings of her study on determinants of this parameter and its association with outcomes in HF patients.

Higher dose of loop diuretics limits uptitration RAASi in HFrEF

5' education - Aug. 20, 2019 - Jozine ter Maaten
Jozine ter Maaten presents the results of her study on the effects of loop diuretics dosage on the ability to uptitrate RAASi in HFrEF patients and the association of loop diuretics dosage with outcomes.

ESC HF 2019 Jozine ter Maaten presents the results of her study on the effects of loop diuretics dosage on the ability to uptitrate RAASi in HFrEF patients and the association of loop diuretics dosage with outcomes.

ARNI as first-line therapy in de novo HFrEF patients after ADHF event

3' education - June 3, 2019
Michele Senni gives a short presentation of a subanalysis of the TRANSITION trial, comparing the rate of patients on sacubitril/valsartan after 10 weeks in de novo vs. previously diagnosed HFrEF patients.

ESC HF 2019 Michele Senni gives a short presentation of a subanalysis of the TRANSITION trial, comparing the rate of patients on sacubitril/valsartan after 10 weeks in de novo vs. previously diagnosed HFrEF patients.

Potassium binder results in more persistent use of spironolactone in resistant hypertension and CKD, also in a group of HF

3' education - June 3, 2019
Prof. Rossignol talks about the AMBER trial and a prespecified analysis of HF patients. Patiromer use resulted in higher spironolactone maintenance in patients with resistant hypertension and CKD.

ESC HF 2019 Prof. Rossignol talks about the AMBER trial and a prespecified analysis of HF patients. Patiromer use resulted in higher spironolactone maintenance in patients with resistant hypertension and CKD.

GRAND DEBATE | Should all patients with HF and AF receive catheter ablation?

ESC Heart Failure 2019, Athens, Greece
ESC Heart Failure 2019, Athens, Greece

ESC HF 2019 In this debate, Douglas Packer and John Cleland took opposite sides of the statement that all patients with atrial fibrillation and heart failure should receive ablation. With poll.

More patients on target dose for ARNI in de novo HFrEF

News - May 25, 2019
In a post-hoc analysis of the TRANSITION trial, a higher proportion patients on target dose for sacubitril/valsartan was observed in //de novo// HFrEF patients compared to prior diagnosed HFrEF patients.

ESC HF 2019 In a post-hoc analysis of the TRANSITION trial, a higher proportion patients on target dose for sacubitril/valsartan was observed in de novo HFrEF patients compared to prior diagnosed HFrEF patients.

Factor Xa inhibitor reduces stroke risk in patients with HFrEF, sinus rhythm and CAD

News - May 25, 2019
A subanalysis of the COMMANDER-HF trial demonstrated that low dose rivaroxaban decreased stroke/TIA risk in patients with HFrEF, sinus rhythm and CAD without increase in major bleeding.

ESC HF 2019 A subanalysis of the COMMANDER-HF trial demonstrated that low dose rivaroxaban decreased stroke/TIA risk in patients with HFrEF, sinus rhythm and CAD without increase in major bleeding.

Use of patiromer results in more patients remaining on spironolactone in resistant hypertension and CKD, with and without HF

News - May 25, 2019
Addition of patiromer to spironolactone showed that a higher percentage of patients remained on spironolactone vs. those on placebo and spironolactone at the start, with no difference between HF or non-HF.

ESC HF 2019 Addition of patiromer to spironolactone showed that a higher percentage of patients remained on spironolactone vs. those on placebo and spironolactone at the start, with no difference between HF or non-HF.

Improvement of medication adherence with pharmacy-based intervention in elderly chronic HF patients

News - May 24, 2019
 In the PHARM-CH trial, a pharmacy-based intervention resulted in higher adherence to 3 HF medication classes in elderly, chronic HF patients and this intervention was safe.

ESC HF 2019 In the PHARM-CH trial, a pharmacy-based intervention resulted in higher adherence to 3 HF medication classes in elderly, chronic HF patients and this intervention was safe.

Classification of acute HF patients based on congestion and hypoperfusion status in real-world setting

News - May 24, 2019
Classification based on congestion and hypoperfusion status was applied to a real-world population of acute HF patients, showing that wet-cold (congestion and hypoperfusion) profile was associated with worst outcomes.

ESC HF 2019 Classification based on congestion and hypoperfusion status was applied to a real-world population of acute HF patients, showing that wet-cold (congestion and hypoperfusion) profile was associated with worst outcomes.